Curis Inc. (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Other equities research analysts have also recently issued research reports about the company. FBR & Co reaffirmed a “buy” rating on shares of Curis in a report on Monday, June 13th. Robert W. Baird reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Curis in a report on Wednesday, September 7th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Curis has an average rating of “Buy” and a consensus price target of $4.56.
Shares of Curis (NASDAQ:CRIS) opened at 2.50 on Monday. The stock’s market capitalization is $323.68 million. The firm has a 50 day moving average price of $1.90 and a 200 day moving average price of $1.77. Curis has a one year low of $1.25 and a one year high of $3.18.
Curis (NASDAQ:CRIS) last released its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The business’s quarterly revenue was down 19.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.06) earnings per share. Analysts predict that Curis will post ($0.38) earnings per share for the current fiscal year.
In other Curis news, major shareholder Discovery Technologie Aurigene bought 10,208,333 shares of the business’s stock in a transaction on Wednesday, September 7th. The stock was bought at an average price of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the purchase, the insider now directly owns 27,328,464 shares in the company, valued at $65,588,313.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.09% of the company’s stock.
Large investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in Curis during the second quarter valued at about $146,000. ProShare Advisors LLC boosted its stake in Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the period. Rhumbline Advisers boosted its stake in Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Curis during the first quarter valued at about $248,000. 52.36% of the stock is owned by institutional investors.
Curis Company Profile
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.